Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management
MA Gertz - American journal of hematology, 2023 - Wiley Online Library
Abstract Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include …
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement
H Hegen, G Arrambide, S Gnanapavan… - Multiple Sclerosis …, 2023 - journals.sagepub.com
Cerebrospinal fluid (CSF) analysis is of utmost importance for diagnosis and differential
diagnosis of patients with suspected multiple sclerosis (MS). Evidence of intrathecal …
diagnosis of patients with suspected multiple sclerosis (MS). Evidence of intrathecal …
[HTML][HTML] Epidemiology, Pathophysiology, and Management of Cancer-Associated Ischemic Stroke
D Ryan, TB Dargham, S Ikramuddin, S Shekhar… - …, 2024 - pmc.ncbi.nlm.nih.gov
Simple Summary Cancer and stroke are leading causes of global disability and mortality.
With improvements in cancer-associated mortality and advancements in treatment of active …
With improvements in cancer-associated mortality and advancements in treatment of active …
[HTML][HTML] Bing–Neel syndrome: update on diagnosis and treatment
EY Wong, S D'Sa, MC Minnema, JJ Castillo… - Hemato, 2022 - mdpi.com
Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström
macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and …
macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and …
Bing-Neel syndrome: real-life experience in personalized diagnostic approach and treatment
D Kotsos, S Chatzileontiadou, A Apsemidou… - Frontiers in …, 2022 - frontiersin.org
The involvement of the central nervous system (CNS) in Waldenström's Macroglobulinemia
(WM) is a rare extramedullary manifestation of the disease known as Bing-Neel syndrome …
(WM) is a rare extramedullary manifestation of the disease known as Bing-Neel syndrome …
[PDF][PDF] Evaluation and Management of Bing–Neel Syndrome
SJ Schep, JMI Vos, MC Minnema - Hematology/Oncology Clinics, 2023 - iwmf.com
Bing–Neel syndrome (BNS) is an uncommon but serious manifestation of Waldenstro m
macroglobulinemia (WM) caused by infiltration of the malignant lymphoplasmacytic cells in …
macroglobulinemia (WM) caused by infiltration of the malignant lymphoplasmacytic cells in …
[HTML][HTML] Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia
N Patel, S Al Hadidi… - Clinical Hematology …, 2024 - pmc.ncbi.nlm.nih.gov
Waldenstrom's macroglobulinemia (WM) or lymphoplasmacytic lymphoma is a B-cell
malignancy characterized by lymphoplasmacytic cells in the bone marrow that secrete high …
malignancy characterized by lymphoplasmacytic cells in the bone marrow that secrete high …
Mixed Diffuse and Tumoral Form of Bing-Neel Syndrome Successfully Treated with Ibrutinib
JA Naveed Ahmad, BA Schroeder, JPT Yun… - Case Reports in …, 2023 - karger.com
Abstract Introduction: Bing-Neel syndrome (BNS) is a rare and heterogenous manifestation
of Waldenström macroglobulinemia (WM) involving central nervous system (CNS) infiltration …
of Waldenström macroglobulinemia (WM) involving central nervous system (CNS) infiltration …
[HTML][HTML] Bing–Neel syndrome, a rare manifestation of WM; a case report and review of literature
H Rezvani, S Salari, H Borhani, M Mataji… - Clinical Case …, 2024 - ncbi.nlm.nih.gov
Bing–Neel Syndrome (BNS) is a rare manifestation of Waldenström macroglobulinemia
(WM) that occurs approximately in 1% of patients with WM. Manifestations can occur …
(WM) that occurs approximately in 1% of patients with WM. Manifestations can occur …
The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia
Abstract The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström's
Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently …
Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently …